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Antigen presenting capacity of murine
splenic myeloid cells
Ying-Ying Hey1,2, Benjamin Quah3 and Helen C. O’Neill2*
Abstract
Background: The spleen is an important site for hematopoiesis. It supports development of myeloid cells from
bone marrow-derived precursors entering from blood. Myeloid subsets in spleen are not well characterised
although dendritic cell (DC) subsets are clearly defined in terms of phenotype, development and functional role.
Recently a novel dendritic-like cell type in spleen named ‘L-DC’ was distinguished from other known dendritic and
myeloid cells by its distinct phenotype and developmental origin. That study also redefined splenic eosinophils as
well as resident and inflammatory monocytes in spleen.
Results: L-DC are shown to be distinct from known splenic macrophages and monocyte subsets. Using a new flow
cytometric procedure, it has been possible to identify and isolate L-DC in order to assess their functional
competence and ability to activate T cells both in vivo and in vitro. L-DC are readily accessible to antigen given
intravenously through receptor-mediated endocytosis. They are also capable of CD8+ T cell activation through
antigen cross presentation, with subsequent induction of cytotoxic effector T cells. L-DC are MHCII− cells and
unable to activate CD4+ T cells, a property which clearly distinguishes them from conventional DC. The myeloid
subsets of resident monocytes, inflammatory monocytes, neutrophils and eosinophils, were found to have varying
capacities to take up antigen, but were uniformly unable to activate either CD4+ T cells or CD8+ T cells.
Conclusion: The results presented here demonstrate that L-DC in spleen are distinct from other myeloid cells in
that they can process antigen for CD8+ T cell activation and induction of cytotoxic effector function, while both
L-DC and myeloid subsets remain unable to activate CD4+ T cells. The L-DC subset in spleen is therefore distinct as
an antigen presenting cell.
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Background
Spleen is a secondary lymphoid organ that specialises in
filtering blood-borne antigen and recycling the heme
group from damaged erythrocytes. The spleen is also im-
portant for myelopoiesis, and myeloid cells are primarily
located within the red pulp region. The white pulp con-
tains the periarteriolar lymphoid sheath in the T-cell
zone, B cell follicles and the marginal zone, located at
the interface of the red pulp and the periarteriolar
lymphoid sheath for screening blood-borne antigens and
pathogens [1, 2]. Multiple subsets of dendritic cells (DC)
have been described in spleen, located mainly within the
white pulp where immune responses against blood-
borne antigens and pathogens are initiated.
The “myeloid” subset in spleen includes granulocytes,
monocytes and macrophages. Granulocytes like neutro-
phils, eosinophils, basophils and mast cells are Ly6G+
cells mainly localised in the red pulp region, with some
cells in transition through the marginal zone into red
pulp [3]. Monocytes develop in bone marrow from a
common myeloid/dendritic cell progenitor [4, 5], and
continuously migrate into blood and spleen as mature
cells [6]. When monocytes enter tissues they terminally
differentiate to give macrophages, although recent evi-
dence suggests that blood precursors may not be the
only source of tissue macrophages, with evidence that
they can derive from endogenous progenitors of yolk sac
and embryonic origin [7–9].
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Two clear subsets of monocytes were originally identi-
fied in blood as the CX3CR1
loLy6Chi inflammatory
monocytes, and the CX3CR1
hiLy6C− resident monocytes
[5, 6]. However, the characterization of monocyte sub-
sets in tissues is still in its infancy, and our own recent
investigations suggest that these early phenotypic de-
scriptors do not exactly mirror the phenotype of similar
subsets in spleen [10]. Current thinking is that inflam-
matory monocytes, now sometimes referred to as “clas-
sical monocytes” [11], home to sites of infection where
they induce an inflammatory response, and may also dif-
ferentiate to give TNF/iNOS-producing dendritic cells
[12]. Resident monocytes are sometimes referred to as
“non-classical monocytes” and migrate under steady-
state conditions as precursors of tissue-resident macro-
phages, for example in liver, spleen, lung and skin [11, 13].
However, there are still gaps in our knowledge of the rela-
tionship between resident macrophages and resident or
non-classical monocytes. Some studies now indicate a
multitude of pathways for development, influenced by en-
vironmental and infectious states, with a recent evidence
for the wound healing capacity of some monocytes. A res-
ervoir of undifferentiated monocytes resident in spleen was
found to be similar to blood monocytes in terms of pheno-
type and gene expression [14]. Monocytes were shown to
mobilise from spleen into sites of inflammation in heart,
with inflammatory monocytes clearing damaged tissues,
and resident monocytes promoting wound healing [14].
Spleen also contains several subsets of resident macro-
phages. Marginal zone metallophilic macrophages stain
with the MOMA-1 antibody and are localised near the
PALS and B cell follicles [15]. These macrophages are
thought to function in induction of cytotoxic T cell re-
sponses against blood-borne and self antigens [15, 16].
Marginal zone macrophages are located closer to red pulp
and express a number of Toll-like receptors (TLR), the
MARCO scavenger receptor and the C-type lectin,
SIGNR1, for clearance of microorganisms [15, 17]. Tangible
body macrophages in the white pulp of spleen are involved
in phagocytosis of apoptotic B cells during germinal center
reactions and can be distinguished as CD11b−F4/80−CD68+
cells [18]. Red pulp macrophages which clear old or dam-
aged red blood cells and recycle of heme groups, are dis-
tinct by F4/80 expression (CD11b+F4/80+CD68+) [2]. In
addition, macrophages can be further classified as
pro-inflammatory (classical) or anti-inflammatory (non-
classical) subsets of M1 and M2 macrophages on the basis
of functions, adding further functional diversification to the
myeloid lineage [19].
Extensive studies on the lineage origin and immune
function of splenic DC subsets has led to definition of
conventional (c) DC and plasmacytoid (p) DC derived
from a common dendritic progenitor in bone marrow
[20, 21]. Plasmacytoid-preDC and pre-cDC can then be
found in blood [22], and precursors enter and mature in
spleen to form three main subsets which activate both
CD4+ and CD8+ T cells [22]. The CD8+ and CD8− sub-
sets of cDC are distinct in production pf interleukin-12
and ability to cross -present antigen to CD8+ T cells
[23], while pDC are strong producers of interferon-α in
response to viral infection [24, 25]. However, monocyte-
derived DC can also form in spleen in response to in-
flammatory stimuli [26], and these are distinguishable
both marker phenotypically and functionally from cDC
[6, 27, 28].
A novel subset of dendritic-like cells, namely L-DC,
has also been identified in both murine and human
spleen [10, 29, 30]. These cells were discovered on the
basis of their resemblance to cells produced in splenic
long term cultures [31, 32]. An equivalent L-DC subset
in spleen has been identified following comprehensive
flow cytometric analysis of many splenic myeloid and
dendritic subsets [10]. That study distinguished L-DC
from cDC subsets, and served to better define the
splenic subsets of inflammatory monocytes, resident
monocytes and eosinophils in mice [10]. L-DC are now
identifiable by their phenotype as CD11bhiCD11cloC-
D43loCX3CR1
lo cells, also lacking expression of MHCII,
Ly6C, Ly6G, and Siglec-F. They are clearly distinct from
inflammatory monocytes, neutrophils and eosinophils on
the basis of phenotype and morphology. Inflammatory
monocytes were found to be phenotypically and mor-
phologically distinct from resident monocytes, Resident
monocytes were found to be more closely related in
phenotype to L-DC than to inflammatory monocytes, al-
though all three subsets were morpologically distinct. In
order to assess the functional role of L-DC in relation to
resident monocytes and other myeloid subsets, pure
populations of cells have been sorted for comparison of
their antigen presenting capacity.
Methods
Animal
C57BL/6J, C57BL/6.Tg(TcraTcrb)1100Mjb (OT-I TCR-
transgenic (TCR-tg) (anti-H-2Kb/OVA257–264), C56BL/6.
SJL/J.OT-II.CD45.1 (OT-II TCR-tg (anti-IAb/OVA323–339)
mice) and C57BL/6-Tg(CAG-OVA)916Jen:WehiAnu (Act-
mOVA) mice were obtained from the John Curtin School
of Medical Research at the Australian National University
(Canberra, ACT, Australia). Mice were housed and han-
dled according to the guidelines of the Animal Experi-
mentation Ethics Committee at the Australian National
University. Mice were euthenased through carbon dioxide
asphyxiation.
Fractionation of cells
Dendritic and myeloid cells were separated from spleno-
cytes via negative depletion of T, B and red blood cells
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using MACS® magnetic bead technology (Miltenyi:
Bergisch Gladbach, Germany). Splenocytes were incu-
bated with red blood cell lysis buffer for 5 minutes and
washed with fluorescence activated cell sorting (FACS)
buffer (1% FSC, 0.1% sodium azide in Dulbecco’s Modified
Eagle Medium). Cells were then stained with 0.25 μg bio-
tinylated anti-Thy1.2 antibody/108 cells (T cells), 0.25 μg
biotinylated anti-CD19 antibody/108 cells (B cells) and
0.25 μg biotinylated anti-Ter119 antibody/108 cells (red
blood cells) in 1 mL FACS buffer for 20 min on ice. Cells
were washed and supernatant aspirated. They were then
resuspended in MACS labelling buffer (2 mM EDTA/0.5%
bovine serum albumin in PBS) at 108 cells/mL and 20 μl
of anti-biotin microbeads/108 cells on ice for 25 min. Cells
were washed twice in MACS buffer and resuspended in
500 μl of buffer prior to running cells through LS columns
(Miltenyi) in a SuperMACS II Separation Unit (Miltenyi).
T, B and red blood cells were removed via binding to
microbeads in the LS columns. The column was washed
thrice with MACS buffer and unbounded cells collected
as flow-through.
CD8+ T cells were isolated from OT-I TCR-tg mice
specific for ovalbumin (OVA)257–264/H-2K
b and CD4+ T
cells were isolated from OT-II TCR-tg mice specific for
IAb/OVA323–339, using MACS magnetic microbead sep-
aration technology as described above. CD8+ T cells
were enriched from splenocytes via negative depletion of
myeloid cells, granulocytes, DC, B cells and CD4+ T cells
using specific antibodies: 0.25 μg biotinylated anti-CD19
antibody/108 cells (B cells), 0.25 μg biotinylated anti-
MHCII antibody/108 cells (DC), 0.25 μg biotinylated
anti-Gr1 antibody/108 cells (granulocytes and myeloid
cells) and 0.25 μg biotinylated anti-CD4 antibody/108
cells. Similarly, CD4+ T cells were enriched by substitut-
ing antibody to deplete CD8+ T cells in the above cock-
tail: 0.25 μg biotinylated anti-CD8 antibody/108 cells.
Flow cytometry
Methods used for antibody staining and flow cytometry
for analysis of cell surface marker expression have been
described previously [10, 33, 34]. Prior to antibody stain-
ing, non-specific antibody binding to cells was inhibited
by absorption of anti-CD16/32 (FcBlock: Biolegend:
San Diego, CA, USA) used at 5 μg/106 cells in 1 mL
of FACS buffer. Fluorochrome- or biotin-conjugated
antibodies specific for CD11c (N418), CD11b (M1/70),
CD8 (53–6.7), CD19 (1D3), CD43 (IBII), F4/80
(CI:A3-1), Ter119 (Ter119), Thy1.2 (30-H12), Siglec-F
(E50-2440), Ly6C (HK1.4), Ly6G (1A8) and I-A/I-E
(M5/114.15.2) were purchased from Biolegend. Anti-
bodies specific for CD68 (FA-11) and SIGN-R1 (ER-
TR9) were purchased from AbD Serotec. Lastly, antibody
specific for MOMA-1 (MOMA-1) was purchased from
AbCam. Propidium iodide (PI) staining prior to flow
cytometry was used to distinguish live and dead cells. Flow
cytometry was performed on a BD LSRII flow cytometer
(Becton Dickinson: Franklin Lakes, NJ, USA). Data were
collected in terms of forward scatter, side scatter and mul-
tiple fluorescence channels. BD FACSDiva Software
(Becton Dickinson) was used to acquire data and analysis
post-acquisition employed FlowJo software (Tree Star:
Ashland, OR, USA).
For sorting, cells were stained with fluorochrome-
labelled antibodies and subsets identified as described in
Hey et al. [10] and summarised in Table 1. All incuba-
tion and washing steps were performed in sodium azide-
free FACS buffer. Sorted populations were collected in
complete medium for use in functional assays.
Endocytosis assay
The capacity of cells to take up antigen in vivo was
assessed by measuring uptake of labelled antigen using
flow cytometry. Ovalbumin conjugated to FITC (OVA-
FITC) was delivered intravenously to mice at 1 mg/mouse
at different time points, as described previously [30], with
spleens collected at the same time (Fig. 2a). Mannan con-
jugated to FITC (mannan-FITC) was a new compound
and so an initial time course study was conducted using
1 mg of mannan-FITC per mouse. A dose response was
then conducted using 3 h as the time for maximum up-
take (Fig. 2b). Splenocytes were prepared by red blood cell
lysis and enrichment of T and B cells by depletion as de-
scribed above. Cells were then stained with specific anti-
bodies to identify subsets and determine uptake of
labelled antigen via flow cytometry.
Cell culture
Cells were cultured in Dulbecco’s Modified Eagle
Medium supplemented with 22.2 mM D-glucose, 13 μM
folic acid, 27 μM L-asparagine, 5.5 mM L-arganine HCL,
Table 1 Phenotypic identification of myeloid and dendritic
subsets in spleen
Subsets Phenotypea
CD8+ cDC CD11b−CD11chiCD8+CD43−Ly6C−Ly6G−MHCII+
CD8− cDC CD11b+CD11chiCD8−CD43−Ly6C−Ly6G−MHCII+
L-DC CD11bhiCD11cloCD8−CD43+Ly6C−Ly6G−MHCII−Siglec-F−
Resident
monocytes
CD11bhiCD11cloCD8−CD43hiLy6C+Ly6G−MHCII−Siglec-F−
Inflammatory
monocytes
CD11bhiCD11c−CD8−CD43+Ly6ChiLy6G−MHCII−Siglec-F−
Eosinophils CD11bhiCD11c−CD8−CD43+Ly6C+Ly6G−MHCII−Siglec-F+
Neutrophil CD11bhiCD11c−CD8−CD43+Ly6C+Ly6G+MHCII−Siglec-F−
a Splenocytes were prepared by removal of red blood cells and T and B
lymphocytes, and then cells stained with cocktails of antibodies for separation
of subsets and sorting using flow cytometry. The phenotype of myeloid
subsets was delineated previously in Hey et al. [10]. The phenotype of cDC
subsets was taken from Merad et al. [56]
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10% heat inactivated fetal calf serum (JRH Biosciences:
Lenexa, Kansas, USA), 10 mM Hepes (JRH Biosciences),
2 mM L-glutamine (JRH Biosciences), 17.1 μM strepto-
mycin, 100U penicillin and 50 μM 2-mercaptoethanol
(BDH Ltd.: Poole, England) per litre of medium. For cul-
ture, cells were maintained in 5% CO2 in air with 97%
humidity at 37 °C.
T cell activation
The ability of sorted dendritic and myeloid cells to acti-
vate T cells was measured by their capacity to induce
antigen-specific activation and proliferation of anti-OVA
CD4+ T cells isolated from OT-II TCR-tg mice, or anti-
OVA CD8+ T cells isolated from OT-I TCR-tg mice.
Dendritic and myeloid subsets were sorted from spleno-
cytes prepared from transgenic Act-mOVA mice. Sorted
cells express OVA peptides on MHCI and MHCII mole-
cules after in vivo uptake and clearance of dead cells in
mice. Thus, cDC isolated from Act-mOVA mice can
cross-present antigen to CD8+ T cells. Antigen present-
ing cells (APC) were sorted as described in Hey et al.
[10] and summarised in Table 1. Cells were plated in di-
luting numbers in the presence or absence of lipopoly-
saccharide (LPS: 10 μg/mL), prior to addition of T cells.
In order to measure proliferation, T cells were labelled
with 5-(and 6-) carboxyfluorescein diacetate succinimi-
dyl ester (CFSE: Molecular Probes: Eugene, Oregon,
USA) as described previously [33]. T cells were labelled
at a final concentration of 2.5 μM CFSE per 107cells/mL in
CFSE labelling buffer (PBS/0.1%BSA). T cells were cocul-
tured with APC and collected after 72 h to determine T cell
proliferation flow cytometrically by quantitation of CFSE
staining. Proliferation was assessed in terms of dilution of
fluorescent stain with each cell division.
Measuring a cytotoxic T cell response in vivo
The ability of APC to induce a cytotoxic T lympho-
cyte response was investigated via lysis of target cells.
Targeted cell lysis was measured using a fluorescent
target array developed by Quah et al. [35]. The
experimental protocol is summarised in Fig. 4a. On
Day 0, CD8+ T cells were isolated from OT-I TCR-Tg
mice. Equal numbers of CD8+ T cells were delivered
into individual host mice (C57BL/6 J) via intravenous
injection (3.5 × 106 cells/mouse). At one hour after
delivery of T cells, APC subsets sorted from Act-
mOVA mice were also delivered into host mice.
Three concentrations of APC were used: 90,000, 9000
and 900 cells. The effector function of activated CD8+
T cells was measured on Day 7 via lysis of peptide-
pulsed target cells adoptively transferred intravenously
on Day 6. Target cells were isolated from B6. SJL
spleen and labelled with CFSE, Cell Trace Violet
(Molecular Probes, Invitrogen) and Cell Proliferation
Dye (eBioscience). Splenocytes were resuspended at 0.5-
2 × 108 cells/mL in 20 °C in medium and labelled with a
final concentration of 0, 400, 2250 and 12,500nM of each
dye. Labelled splenocytes were pulsed with SIIN (SIIN-
FEKL), N6 (SIINFNKL), G4 (SIIGFEKL) and E1 (EIIN-
FEKL), respectively, for an hour at 37 °C. All peptides
were synthesised at the Biomolecular Research Facility
(Australian National University). Pulsed target cells (2.5 ×
107) were delivered intravenously into host mice one day
prior to harvesting host splenocytes for flow cytometric
analysis of target cells. Flow cytometry was used to esti-
mate the total number of target cells left in spleen. Spe-
cific killing of target cells was determined by the following
formula which has been described previously [35].
% specific lysis ¼ 1−
Targets
primed
þpeptide
Targets
primed
þnil
Targets
naive
þpeptide.
Targets
naive
þnil
0
BBBBB@
1
CCCCCA
2
666664
3
777775
 100
Statistical analysis
Data have been presented as mean ± standard error for
sample size n. Where a normal distribution could be as-
sumed, Students’ t-test was used to determine signifi-
cance (p ≤ 0.05). For sample size n ≤ 5, where normal
distribution cannot be assumed, the Wilcoxon Rank
Sum test was used to test significant (p ≤ 0.05).
Results
Phenotypic identification of dendritic and myeloid
subsets in spleen
A combination of cell surface markers was used to iden-
tify DC and myeloid subsets in spleen following a recent
published procedure [10]. Conventional DC were gated
as CD11chiMHCII+ cells, then further delineated to give
CD8+ cDC and CD8− cDC on the basis of CD8 and
CD11b expression (Table 1). Myeloid cells were initially
gated as CD11bhiCD11c− cells, then further delineated
to give neutrophils, inflammatory monocytes and eosin-
ophils on the basis of Ly6C, Ly6G and Siglec-F expres-
sion (Table 1). While L-DC and resident monocytes
share a common CD11bhiCD11clo profile, they can be
distinguished on the basis of Ly6C, Ly6G, CD43 and
CX3CR1 expression (Table 1) [10].
L-DC are distinct from splenic macrophages
Macrophages have been historically characterised in
spleen by immunohistological analysis. While some
macrophage-specific markers have been identified, macro-
phage subsets are not well defined. Expression of markers
like MOMA-1, SIGNR1, CD68 and F4/80 was therefore
investigated on splenocytes. For each of the four macro-
phage markers, marker positive cells were initially gated
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and found to display a majority phenotype (40–50%) as
CD11b+CD11c−Ly6C+/−Ly6G− macrophages (data not
shown). Subsequently, myeloid subsets and L-DC were
gated as described in Table 1 and Hey et al. [10], and
assessed for expression of specific macrophage markers
(Fig. 1). Gated inflammatory monocytes, eosinophils and
neutrophils did not stain for any of the macrophage
markers, except F4/80. However, all gated myeloid and
DC subsets stained for F4/80, and this is consistent with
multiple studies which have demonstrated that F4/80
staining is not restricted to red pulp macrophages
[36–38]. Neither resident monocytes, cDC nor L-DC
showed expression of macrophage specific markers (Fig. 1).
Antigen uptake capacity of L-DC compared with myeloid
subsets
A primary function of spleen is to filter and trap blood-
borne antigens, and this involves uptake and processing
of antigen by dendritic and myeloid cells. Antigen pre-
senting cells express a combination of receptors for up-
take of antigen of different type via different pathways
for endocytosis. In this study, pinocytosis and receptor-
Fig. 1 Expression of macrophage specific markers. Splenocytes were clear of red blood cells by lysis and enriched for myeloid and DC subsets via
T and B cell depletion. Cells were then stained with fluorochrome-conjugated antibodies specific for CD11b (PE-Cy7), CD11c (APC), Ly6C (FITC),
Ly6G (PE), along with biotinylated antibodies to CD68, MOMA-1, SIGNR1 and F4/80. APC-Cy7-streptavidin was used as a secondary conjugate.
L-DC, dendritic and myeloid subsets were gated as described in Table 1 and Hey et al., (2016) [10]. a Expression of CD68, MOMA-1, SIGNR1 and
F4/80 on inflammatory monocytes (Infl mono), eosinophils (Eos), neutrophils (Neu) and macrophages (Macro). b Expression of CD68, MOMA-1,
SIGNR1 and F4/80 on resident monocytes (Resi mono), L-DC and cDC subsets. Data are reflective of three independent analyses
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mediated endocytosis of antigen were investigated for
the splenic myeloid subsets described in Table 1. FITC-
labelled antigens were delivered intravenously into mice
with subsequent isolation of subsets to compare uptake
over time. Pinocytosis was studied by uptake of OVA-
FITC as a soluble antigen under conditions described
previously [30]. Amongst the splenic myeloid subsets,
both resident and inflammatory monocytes showed abil-
ity to endocytose and retain OVA, with resident mono-
cytes the most potent (Fig. 2a). Only ~10% of
neutrophils and eosinophils took up and retained OVA
(Fig. 2a). Their endocytic capacity was relatively weak
compared with monocytes (Fig. 2a). L-DC displayed
some uptake of OVA, but the level was relatively low
compared with monocytes (Fig. 2a).
Mannose receptor-mediated uptake of antigen in DC
has been found to contribute to cross-presentation of anti-
gen to CD8+ T cells [39, 40]. Cross-presentation is a defin-
ing property of DC, and is clearly a property of splenic
CD8+ cDC [23]. In order to determine if L-DC and other
myeloid subsets can endocytose antigen via mannose re-
ceptors, mannan-FITC was prepared and delivered intra-
venously to mice and cell uptake monitored in a pilot
study to determine optimal time for uptake. A further ex-
periment using a 3 h time for uptake, then determined the
minimum saturating dose of FITC-mannan as 0.1 mg per
mouse. In the time course study, both resident and
inflammatory monocytes demonstrated the strongest abil-
ity to take up mannan, with >75% uptake after 1 h, and
>50% of resident monocytes retaining mannan after 6 h
(Fig. 2b). In contrast, inflammatory monocytes displayed
peak uptake of 88% at 3 h, with retention of antigen for
6 h by ~50% of cells (Fig. 2b). Delayed uptake by inflam-
matory monocytes, could reflect lower accessibility to
antigen in comparison with resident monocytes. About
35% of eosinophils took up mannan by 3 h after delivery,
but this diminished by 6 h (Fig. 2b). Neutrophils showed
no endocytosis of mannan-FITC. Notably, L-DC showed
high ability to take up and retain mannan although at
lower levels than monocytes (~50%) (Fig. 2b). In the dose
response experiment, both L-DC and resident monocytes
gave strong early uptake, while inflammatory monocytes
required infusion of more FITC-mannan to reach the
same level of uptake (Fig. 2b). In an in vivo assay of this
type, the level of mannan in cells is indicative of both the
accessibility of cells to blood-borne antigen and the endo-
cytic ability of cells. Resident monocytes took up and
retained the highest level of mannan, followed by inflam-
matory monocytes, then L-DC (Fig. 2b).
Ability of splenic myeloid and DC subsets to activate CD4+
T cells
A known property of antigen presenting DC and some
macrophages is their ability to process exogenous
Fig. 2 Comparison of endocytic ability of myeloid and dendritic subsets. The ability of cells to endocytose antigen was measured by uptake of
OVA-FITC and mannan-FITC. Spleens were collected for analysis at the same time, and splenocytes prepared by lysis of red blood cells with
enrichment for dendritic and myeloid cells via T and B cell depletion. Cells were stained with antibodies to identify L-DC and myeloid subsets as
shown in Table 1. Uptake of antigen was assessed in terms of % FITC staining cells. C57BL/6 J mice were given: a OVA-FITC at 1, 3, and 6 h prior
to euthanasia for spleen collection (intravenously; 1 mg per mouse). Data reflect mean ± SE (n = 4); b mannan-FITC (intravenously; 0.5 mg per
mouse) at 1, 3 and 6 h prior to euthanasia for spleen collection. Single mice only were analysed tin a pilot study to determibe optimal time of
3 h used in a subsequent dose response experiment. Data reflect mean ± SE (n = 2). Control mice were given PBS
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antigen and present it as peptides on MHC-II molecules
for CD4+ T cell activation. Previously it was shown that
L-DC generated in vitro in long-term splenic cultures,
or in stromal co-cultures, lack ability to activate CD4+ T
cells, consistent with their absence of cell surface MHC-
II expression [30, 33, 41]. Improved methodology for
distinguishing dendritic and myeloid subsets in spleen
now allows the question of the antigen presenting cap-
acity of different subsets to be addressed with more cer-
tainty. The Act-mOVA mouse model was employed as a
source of OVA antigen-expressing APC. Splenic myeloid
and DC subsets were therefore sorted from Act-mOVA
mice according to the criteria shown in Table 1, and
compared for capacity to induce proliferation of CD4+ T
cells isolated from OT-II TCR-tg anti-OVA mice.
Consistent with the literature [42], CD8− cDC were
found to be very strong inducers of CD4+ T cell prolifer-
ation (Fig. 3). Neutrophils, inflammatory monocytes and
eosinophils induced no CD4+ T cell proliferation. L-DC
and resident monocytes induced no or very low levels of
CD4+ T cell proliferation, equivalent to the control
population of only T cells (Fig. 3). The addition of lipo-
polysaccharide (LPS) as a stimulator of APC did not im-
prove the activation of CD4+ T cells, except in the case
of CD8− cDC where there was a minor increase at the
highest T cell: APC ratio (Fig. 3). L-DC and monocyte
subsets lacked ability to activate CD4+ T cells, despite
their ability to endocytose and process mannan as an
antigen, or OVA as a soluble antigen in the case of resi-
dent monocytes. Inability to activate CD4+ T cells is also
consistent with lack of MHC-II expression by L-DC and
the two monocyte subsets. These data serve to distin-
guish L-DC from professional APC like cDC.
Can L-DC cross present antigen for CD8+ T cell activation?
Cross presentation appears to be a property of DC, and
has been clearly demonstrated for the CD8α+ subset of
cDC [42–44]. Early studies suggested that cross presen-
tation was restricted to DC [45], although some macro-
phage and neutrophil subsets were found to have cross
presenting ability under specific conditions [45–50]. The
techniques used to isolate pure subsets of cells in those
earlier studies were not as specific as those used here.
The cross presenting ability of L-DC and the myeloid sub-
sets listed in Table 1 has been assessed in relation to CD8+
cDC. Subsets were isolated from Act-mOVA mice and
used to activate purified OTI (TCR-tg; anti-OVA) CD8+ T
cells. T cells and APC were co-cultured for 72 h at ratios
of 33, 100, 300 and 900:1 T cells:APC. The % proliferation
of T cells was measured, and the ratio of T cell/APC re-
quired to induce 50% proliferation of CD8+ T cells used to
compare data across replicate experiments (Table 2). The
Fig. 3 Activation of CD4+ T cells by splenic dendritic and myeloid subsets. Antigen presenting ability of myeloid subsets purified from spleens of
Act-mOVA mice was assessed. L-DC, eosinophils (Eos), inflammatory monocytes (Infl mono), neutrophils (Neu), resident monocytes (Resi mono)
and CD8− cDC (as a control), were sorted as described in Table 1 following enrichment of splenocytes by depletion of red blood cells and T and
B lymphocytes using magnetic bead technology. Diluting numbers of APC were plated following treatment with LPS (10 μg/ml) (solid line) and
without LPS (dotted line) for 2 h. This was followed by addition of 105 CFSE-labelled OT-II (TCR-tg) CD4+ T cells purified from mouse spleen
through depletion of B cells, CD8+ T cells, DC and myeloid cells using magnetic bead protocols. Cells were cultured at T cell:APC ratios of 33:1,
100:1, 300:1 and 900:1 for 72 h. CD4+ OT-II T cells were then gated as PI−Thy1.2+Vα2+CD8− cells, and assessed flow cytometrically for CFSE dilution
as an indicator of T cell proliferation. OT-II T cells cultured alone served as controls (con). Graphs show % proliferating OT-II cells. Two
independent replicate experiments were conducted
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assay was performed in the presence and absence of LPS
which can act as a potent inflammatory stimulus for some
APC [51]. Consistent with previous reports in the literature,
CD8+ cDC were superior in their ability to cross present
antigen for CD8+ T cell activation and proliferation
(Table 2), and this was shown over 6 independent experi-
ments. In these experiments, neutrophils and inflammatory
monocytes did not induce T cell proliferation through cross
presentation of antigen. L-DC were up to 3-fold better acti-
vators of T cell proliferation than resident monocytes, but
also 3-fold less effective than cDC in cross presentation of
antigen for CD8+ T cell activation. In most experiments,
the proliferation of T cells was not increased in the pres-
ence of LPS, suggesting it is not an activator of most of the
APC subsets tested here. While outcomes from different
experiments varied slightly, there was an overall trend
showing that L-DC were better APC than resident mono-
cytes, but were less effective than cDC. Inflammatory
monocytes and neutrophils did not activate T cells.
Induction of cytotoxic T cells by L-DC
The ability of APC to induce cytotoxic effector function
along with proliferation of CD8+ T cells was tested by
adoptive transfer in vivo. Experiments compared the
ability of L-DC, resident monocytes and CD8+ cDC to
induce cytotoxic effector function in CD8+ T cells using
an in vivo cytotoxic killing assay developed by Quah et al.
[35]. Sorted CD8+ OT-I (TCR-tg; anti-OVA) T cells
were delivered intravenously into mice one hour ahead
of APC sorted from ACTm-OVA mice as described in
Table 1. Three doses of sorted APC were given to mice:
90,000, 9,000 and 900 cells. Six days later, labelled
peptide-pulsed splenocytes were delivered intravenously
to act as target cells for cytotoxic effectors primed by
the sorted APC (Fig. 4a). At 1-day after delivery of tar-
get cells, host splenocytes were harvested to quantitate
number of viable target cells in spleen to estimate % tar-
get cell lysis (Fig. 4). Ahead of adoptive transfer, target
splenocytes were labelled with three different dyes used
at four different concentrations. These were then pulsed
with four different OVA peptides, either (SIIN) SIIN-
FEKL, N6 (SIINFNKL), G4 (SIIGFEKL) or E1 (EII-
FEKL), used at six different concentrations, so creating
a multiplex assay. OT-I T cells can recognise the SIIN
peptide but not the G4 and E1 peptides included as
negative controls. The N6 peptide is a variant of SIIN
peptide with phenylalanine and glutamic acid removed,
which is also recognised by OT-I T cells. The response
to N6 peptide determined in this in vivo response was
of similar magnitude to that induced by the specific
SIIN peptide. This could be a feature of this highly
sensitive in vivo cytotoxic T cell assay [35].
The APC subsets of L-DC, resident monocytes and
CD8+ cDC each induced cytotoxic T lymphocytes which
then lysed target cells pulsed with SIIN and N6 peptides,
but not target cells pulsed with the G4 or E1 peptides
(Fig. 4b). In addition, the level of lysis of target cells re-
duced with decreasing concentration of peptides used to
pulse APC, and the number of APC used to prime host
mice (Fig. 4b). In order to directly compare APC sub-
sets, the concentration of peptide required to prime
cytotoxic T cells for 50% lysis of target cells was deter-
mined for each APC. With the N6 peptide, cytotoxic T
cells generated by priming with 9,000 resident mono-
cytes required 100 times more peptide to induce 50%
lysis of target cells in comparison with L-DC and CD8+
cDC (Table 3). After priming with 90,000 APC, cytotoxic
T lymphocytes generated using CD8+ cDC as APC, re-
quired 10 times more SIIN peptide to give 50% lysis of
target cells in comparison with L-DC and resident
monocytes (Table 3). When the number of priming APC
was reduced to 9,000, cytotoxic T cells generated by resi-
dent monocytes required a higher concentration of SIIN
to induce 50% lysis of target cells when compared with L-
DC and CD8+ cDC (Table 3). Overall, resident monocytes
were weaker inducers of a cytotoxic T lymphocyte re-
sponse in comparison with L-DC and CD8+ cDC, which
appear to induce similar cytotoxic effector responses.
Discussion
Spleen plays a central role in immunity to blood-borne
pathogens and cancer antigens. Ineffective immunity to
Table 2 Cross priming capability of L-DC compared with mye-
loid cells
Expt Condition T cell: APC ratio giving 50% maximum proliferation of
OT-I T cellsab
L-DC Resi Mono Infl mono Neu cDC
I + LPS 33 - - 33 300
- LPS 33 - - <33 300
II + LPS 33 33 - - 300
- LPS 33 <33 - - 300
III + LPS 100 42 - - 300
- LPS 100 42 - - 141
IV + LPS 100 42 <33 - 300
- LPS 100 33 <33 - 300
V - LPS 100 33 0 <33 -
VI + LPS 141 0 - <33 -
- LPS 100 0 - <33 -
aFor preparation of APC, splenocytes were harvested from Act-mOVA mice and
prepared by red blood cell lysis followed by T and B cell depletion. L-DC, cDC,
resident monocytes (Resi mono), inflammatory monocytes (Infl mono), neutro-
phils (Neu) were sorted as described in Table 1
b APC, with and without LPS (10ug/ml), were cocultured with 105 CFSE-
labelled OT-I (TCR-tg) CD8+ T cells, sorted as PI−Thy1.2+Vα2+CD4− cells, at T
cell:APC ratios of 33, 100, 300 and 900:1. After 72 h, CD8+ OT-I T cells were
gated as PI−CD11b−Thy1.2+Vα2+ cells, and CFSE dilution assessed flow
cytometrically to estimate % proliferating T cells. OT-I T cells alone served as a
control (Con)
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bacteria at the level of spleen results in sepsis which can
be both lethal and a costly complication of surgery and
emergency medicine. Perisinusoidal niches housing
hematopoietic stem cells were recently described in
spleen red pulp [52], and this finding now opens fresh
debate about the specific contribution of spleen to mye-
lopoiesis and immunity. While the DC subsets in spleen
have been well defined, other myeloid cells have not
been systematically identified, with subset characterisa-
tion based only on the phenotype of similar cells in
blood. With recent systematic identification of dendritic
and myeloid subsets in spleen, and redefinition of
monocytes and eosinophils [10], it is now possible to
compare these subsets in terms of their capacity to up-
take antigen, to activate CD4+ T cells, and to cross prime
CD8+ T cells.
Several distinct dendritic and myeloid subsets were com-
pared initially for capacity to endocytose antigen in vivo.
While L-DC and resident monocytes have a similar CD11clo
CD11bhiMHCII− phenotype, differing in expression of
Fig. 4 Ability of splenic APC to induce a cytotoxic T cell response. The ability of APC subsets to induce cytotoxic effector function in CD8+ T cells was
assessed by measuring lysis of OVA peptide-pulsed target cells in a fluorescent target assay (FTA). a The experimental procedure is shown as a timeline. On
Day 0, CD8+ T cells from OT-I TCR-Tg mice were prepared by red blood cell lysis of splenocytes and sorting for PI−Thy1.2+Vα2+CD4− cells. OT-I T cells
(3.5 × 106) were delivered intravenously into host mice (C57BL/6). An hour later, several APC subsets sorted from Act-mOVA mice were also delivered into
host mice. These were sorted as described in Table 1 and three cell doses (90 K, 9 K or 0.9 K) given intravenously. In order to measure the effector function
of activated CD8+ T cells after 7 days, B6. SJL splenocytes were prepared as targets and adoptively transferred intravenously on Day 6. Target cells were
labelled with several concentrations of CFSE, CTV and CPD for later identification. Overall, labelled target cells were then pulsed with 6 different
concentrations of 4 distinct OVA peptides: SIINFEKL (SIIN), GLEQLESIINFEKL (N6), SIIGFEKL (G4) and EIINFEKL (E1). Specific killing of the distinctly labelled,
antigen-pulsed target cells was determined by flow cytometric analysis to determine the number of target cells remaining in the test mouse compared
with the control mouse given OT-I T cells only. Calculation of target lysis involved the formula described in Materials and Methods. b Data shows % specific
lysis of target cells pulsed with different concentrations of peptides by OT-I T cells primed with three different APC types. Data is expressed as
mean ± SE (n= 6)
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Ly6C, CD43 and CX3CR1 (Table 1), they have very distinct
antigen uptake abilities. Resident monocytes demonstrated
superior ability to pinocytose soluble antigen in vivo, while
L-DC were very weak, like eosinophils and neutrophils.
However, L-DC and resident monocytes both showed high
capacity for uptake of antigen by receptor-mediated endo-
cytosis. Despite this similarity, only L-DC and not resident
monocytes, could activate CD8+ T cells and induce cyto-
toxic effector cells. L-DC were also distinct from neutrophils
which did not undergo receptor-mediated endocytosis or
cross presentation. As shown previously by others, CD8+
cDC were highly endocytic of both soluble and particulate
antigen, although resident and inflammatory monocytes
demonstrated stronger receptor-mediated uptake. Previ-
ously, antigen uptake via mannose receptors was correlated
with cross priming ability in DC [39, 40], although that
study did not investigate the comparative ability of other
myeloid subsets. Here we have been able to demonstrate
that both resident and inflammatory monocyte subsets can-
not cross prime CD8+ T cells, despite strong ability to take
up antigen via mannose receptors. This suggests that cross
presentation of antigen is unlinked to that antigen uptake
pathway, and may require specific uptake or processing
mechanisms.
One main aim of this project has been to compare
L-DC with resident monocytes and cDC subsets in
terms of capacity for T cell activation. A major limitation
for in vitro studies of antigen presentation has been the
low number of dendritic and myeloid cells present in
spleen, and the difficulty of their isolation. Both CD8+
cDC and L-DC are very rare cell types, representing <1%
of splenic leukocytes, and resident monocytes represent a
3-4-fold smaller population [10]. In order to overcome the
limitation of low cell numbers, the Act-mOVA mouse
model was used as a source of APC. These mice constitu-
tively express high levels of cell-associated OVA under the
actin promotor, and isolated APC express OVA peptides
in association with MHCI and MHCII, without the need
for antigen pulsing and washing of cells. In the animal,
APC acquire OVA as an exogenous antigen through up-
take of dead and dying cells then presented on MHCI and
MHCII. However, when OVA is transcribed and expressed
within the cell, there is also the possibility that OVA en-
ters the endogenous antigen processing pathway whereby
defective OVA is ubiquitin tagged for destruction in the
cytoplasm. Since this type of processing could occur in all
cells including APC, it has been necessary to use a control
cell population as an indicator of endogenous cross pres-
entation. In experiments described here, neutrophils
which do not cross present antigen in the steady-state
have served as an adequate control. In all experiments
they induced little or no response in either CD8+ or CD4+
T cells.
Activation of CD4+ T cells is essential for induction of T
helper cells, which then activate B cells and macrophages.
Both CD8+ and CD8− cDC induce activation of CD4+ T
cells, although CD8− cDC have been described as the
strongest inducers [53]. Consistent with those findings,
CD8− cDC were shown to be strong activators of CD4+ T
cells, while L-DC which lack MHCII expression show no
capacity common to other MHCII− myeloid cell types like
eosinophils, neutrophils, inflammatory monocytes and
resident monocytes. This is consistent with previous find-
ings on L-DC produced in longterm spleen co-cultures,
and in spleen stromal co-cultures [30, 33, 41].
While cross presentation is recognised as a character-
istic property of DC, questions still remain as to the
cross presenting capability of monocytes/macrophages
and other myeloid subsets. Interpretation of published
data is limited by the purity and certainty of subsets iso-
lated for analysis, and of the conditions under which
cells have been assessed. Indeed, a number of studies
have described macrophages and neutrophils as able to
cross present antigens to CD8+ T cells under inflamma-
tory conditions. For example, it was recently shown that
neutrophils from inflammatory peritoneal exudates
could cross-prime CD8+ T cells both in vivo and in vitro
[46, 54], While those studies demonstrated cross-
priming by neutrophils, the described response occurred
only under inflammation and so would not be reflective
of neutrophils in steady-state spleen. Here two distinct
assays have been used to analyse cross presenting ability,
Table 3 Capacity of splenic subset to induce a cytotoxic T cell
response
Peptide No. APC from
Actm-OVA mice
used for priminga
Targets:
Concentration of peptide (uM) required
to activate CTL for 50% lysis of targets
L-DC Resi Mono CD8+cDC
SIIN 90 K 0.1 0.1 1.0
9 K 10.0 > > 10 10.0
0.9 K 0 0 0
N6 90 K 0.001 0.001 0.001
9 K 0.01 1.0 0.01
0.9 K 0 0 0
G4 90 K 0 0 0
9 K 0 0 0
0.9 K 0 0 0
E1 90 K 0 0 0
9 K 0 0 0
0.9 K 0 0 0
a The table summarises data obtained from the fluorescent target experiment
described in Fig. 3. Mice were given sorted OT-I CD8+ T cells ahead of APC
sorted from Act-mOVA mice. These included L-DC, Resident monocytes (Resi
mono) and CD8+ cDC. Target cells were added after 6 days, and their lysis
measured in terms of % cell recovery at 24 h
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involving both in vitro and in vivo analyses, and meas-
urement of a response in terms of both T cell prolifera-
tion and induction of T cell cytotoxicity. Both of these
approaches have demonstrated the capacity of both cDC
and L-DC to cross present antigen. Resident monocytes
were quite distinctly different, at least 10-fold weaker
then cDC, and 3- or 10-fold weaker than L-DC across
two assays. Inflammatory monocytes and neutrophils
were also incapable of cross presentation, and at least
10-fold weaker than cDC in inducing T cell proliferation.
The treatment of all APC subsets with LPS did not im-
prove activation of CD8+ T cells. Since L-DC were
insensitive to LPS activation, it is unlikely that L-DC are
monocyte-derived DC.
Cross priming for activation of CD8+ T cells is essen-
tial in the generation of cytotoxic T lymphocytes [55].
Cytotoxic T lymphocytes play an important dual func-
tional role in maintaining self-tolerance by lysing self-
targets and infected or cancerous cells. The ability of
APC to cross present antigen and to induce cytotoxic T
lymphocytes was investigated using a fluorescent target
array which assesses cytotoxic T cell formation within
the animal, where lytic activity against target cells is dir-
ectly measured [35]. Cytotoxic T lymphocytes generated
by OVA-expressing L-DC, lysed target cells pulsed with
the SIIN and N6 peptides of OVA, but not with the G4
and E1 peptides. The cytotoxic T cell response induced
was antigen-specific, since OT-I CD8+ T cells can only
recognise SIIN and N6 peptides in the context of MHCI.
Similarly, both CD8+ cDC and resident monocytes gen-
erated cytotoxic T lymphocytes which gave antigen-
specific lysis of target cells when 9,000 APC were used,
although at 90,000 APC, the activation capacity of CD8+
cDC was 10-fold lower. We attribute this to a saturation
response in the presence of too many cells and too
much peptide antigen. However, resident monocytes re-
quired a much higher concentration of peptide on target
cells to give a similar level of lysis. Thus, resident mono-
cytes are weaker inducers of cytotoxic T lymphocytes
than both L-DC and CD8+ cDC, consistent with their
lack of cross-presenting ability. These data serve to func-
tionally distinguish the L-DC and resident monocyte
subsets despite their similar but distinct phenotypes.
Conclusion
This study identifies the distinct functional capacity of
L-DC in terms of antigen presenting ability for CD4+
and CD8+ T cells. L-DC have been shown to be both
phenotypically and functionally distinct from cDC sub-
sets, resident and inflammatory monocytes, as well as
neutrophils and eosinophils. They are not macrophages
since they do not express markers which identify macro-
phage subsets unique to spleen. L-DC reflect a unique
subset of cells resembling myeloid cells by phenotype,
but a dendritic-like cell in terms of morphology, func-
tion in cross presentation, and ability to induce a cyto-
toxic T cell response.
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